New contracts for EPPS
received $1.8 million (€1.5m) in late-stage development contracts
for active pharmaceutical ingredients (API).
EaglePicher Pharmaceutical Services (EPPS) of the USA says it has received $1.8 million (€1.5m) in late-stage development contracts for active pharmaceutical ingredients (API).
The company said the new projects fall within product development, one of its core businesses, but would not give further details. The company's other interests include radiochemistry and the manufacture of cytotoxic compounds for anticancer applications.
Steve Westfall, president of EPPS, said: "We not only deliver advanced APIs with high, consistent quality, but we also assist our customers with comprehensive regulatory support."
He said that EPPS products are manufactured in strict compliance with current Good Manufacturing Practices and that the company boasts an excellent compliance record. Recent inspections by the US Food and Drug Administration (FDA) of EPPS' facilities found no violations at one of its facilities and only minor infractions at its second site which were corrected during the inspection.
